REFILE-UPDATE 1-Swiss biotech AC Immune taps U.S. IPO to fund Alzheimer's drugs

June 1 (Reuters) - Switzerland's AC Immune, which already has money in hand from Roche for its most advanced drug, is planning a share sale in the United States to raise up to $50 million for separate drug candidates targeting Alzheimer's disease.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.